Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05MGQ
|
|||
| Former ID |
DIB006245
|
|||
| Drug Name |
MDX-1342
|
|||
| Synonyms |
Anti-CD19 (cancer), MDX/BMS; Anti-CD19 antibody (cancer), Medarex/BMS
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 2 | [1] | |
| Company |
Medarex
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | . | [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01974479) Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.